Fulgent Genetics Q3 2026 net loss widens 99% to $13.15 million

Bitget2026/11/05 21:29

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Fulgent Genetics' third-quarter 2026 net loss widened 99% year over year to $13.15 million.
Revenue rose 8% year over year to $90.41 million.
CEO Ming Hsieh highlighted momentum in the therapeutics pipeline and continued AI integration into laboratory workflows.
Full-year 2026 revenue is expected to reach $330 million-$340 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulgent Genetics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261105293387) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Fulgent Genetics Q3 2026 net loss widens 99% to $13.15 million

You may also like

Crypto prices